2022, a year of high impact strategic projects

2021 BioRegion of Catalonia Report

Biocat presented the BioRegion Report in January, with collaboration from AMGEN, CataloniaBio & HealthTech and ACCIÓ, and support from Alira Health, EATRIS-Plus, EY and PONS IP. The document, which Biocat has published since 2009, features the main data on the life sciences and healthcare sector in Catalonia.

Record investment in the BioRegion

The 2021 BioRegion of Catalonia Report, promoted by Biocat, was presented in January in order to announce the most significant data on the Catalan ecosystem. The event took place at the AXA Auditorium, with 300 people in the audience and more following the live stream.

In 2021, startups in the BioRegion raised €238 million in investment, the most to date, of which €187 million was from venture capital. Of all the operations, 83% included foreign investors, mainly from Europe (51) and the United States (31). Over the course of the year there were 36 operations, fewer than the previous year (41) but worth more each on average.
The subsector with the most investment was medical technology, which saw a x2.4 increase from 2020, and digital health companies nearly doubled the investment secured, at over €60 million.

Check out the BioRegion Report

€0

million invested

operations

of operations with international investment

Audience at the presentation of the 2022 BioRegion of Catalonia Report.

Biocat CEO Robert Fabregat at the presentation of the 2022 BioRegion of Catalonia Report.

Robert Fabregat (Biocat), Jaume Amat, (CataloniaBio & HealthTech), Natàlia Mas, (Government of Catalonia and ACCIÓ) and Silvia Ondategui, (Ernst & Young).

During the presentation, there were two panel discussions. The first, “Hi I’m a SME, where is my fast track?” analyzed models from various countries to facilitate market access for digital health and medical technology.

The second, titled “The BioRegion’s Next Generation commitment: a hub of excellence in emerging therapies and personalized medicine” presented the BioRegion’s goal to position itself as a leading European hub and global benchmark in emerging therapies and personalized medicine, and the importance of Next Generation funds in achieving it.